Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD5 CAR T lymphocytes MB-105

A preparation of genetically modified autologous T cells expressing a chimeric antigen receptor (CAR) directed against cluster of differentiation 5 (CD5), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD5 CAR T lymphocytes MB-105 target and bind to CD5-expressing tumor cells, thereby inducing selective cytotoxicity in CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T cells and overexpressed on various B- and T-cell malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD5 CAR T cells MB-105
autologous anti-CD5 CAR-T cells MB-105
autologous CD5-specific CAR T cells MB-105
autologous CD5-targeted CAR-T cells MB-105
autologous CD5CAR-expressing T lymphocytes MB-105
Code name:MB 105
MB-105
MB105
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search